United States securities and exchange commission logo





                            December 8, 2022

       Quang Pham
       Chief Executive Officer
       Cadrenal Therapeutics, Inc.
       822 A1A North, Suite 320
       Ponte Vedra, FL 32082

                                                        Re: Cadrenal
Therapeutics, Inc.
                                                            Amendment No. 3 to
Registration Statement on Form S-1
                                                            Filed December 6,
2022
                                                            File No. 333-267562

       Dear Quang Pham:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 3 to Registration Statement on Form S-1

       Cover Page

   1.                                                   Disclose whether your
offering is contingent upon final approval of your Nasdaq listing
                                                        on your cover page.
Please ensure the disclosure is consistent with your underwriting
                                                        agreement.
       Risk Factors
       Our stock price may be extremely volatile, and your investment in our
common stock could
       suffer a decline in value. , page 44

   2.                                                   We note recent
instances of extreme stock price run-ups followed by rapid price declines
                                                        and stock price
volatility seemingly unrelated to company performance following a
                                                        number of recent
initial public offerings, particularly among companies with relatively
 Quang Pham
Cadrenal Therapeutics, Inc.
December 8, 2022
Page 2
      smaller public floats. Please revise this risk factor or include a
separate risk factor
      addressing the potential for rapid and substantial price volatility and
any known factors
      particular to your offering that may add to this risk and discuss the
risks to investors when
      investing in stock where the price is changing rapidly. In addition,
please clearly state that
      there is a risk of rapid and substantial price volatility and that any
such volatility,
      including any stock-run up, may be unrelated to your actual or expected
operating
      performance and financial condition or prospects, which could make it
difficult for
      prospective investors to assess the rapidly changing value of your stock.
       You may contact Ibolya Ignat at 202-551-3636 or Al Pavot at 202-551-3738
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Dillon Hagius at 202-551-7967 or Jason Drory at 202-551-8342 with any other
questions.



                                                             Sincerely,
FirstName LastNameQuang Pham
                                                             Division of
Corporation Finance
Comapany NameCadrenal Therapeutics, Inc.
                                                             Office of Life
Sciences
December 8, 2022 Page 2
cc:       Leslie Marlow
FirstName LastName